Elanco Animal Health Incorporated (ELAN)

US — Healthcare Sector
Peers: RDY  VTRS  EHC  SOLV  NBIX  RVTY  QGEN  ENSG  ALGN  RVMD 

Automate Your Wheel Strategy on ELAN

With Tiblio's Option Bot, you can configure your own wheel strategy including ELAN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ELAN
  • Rev/Share 9.2411
  • Book/Share 13.5849
  • PB 1.6415
  • Debt/Equity 0.5962
  • CurrentRatio 2.4007
  • ROIC -0.0705

 

  • MktCap 11080055448.0
  • FreeCF/Share 0.7287
  • PFCF 30.6079
  • PE 307.74
  • Debt/Assets 0.297
  • DivYield 0
  • ROE 0.0055

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ELAN Barclays -- Overweight -- $30 Dec. 9, 2025
Initiation ELAN KeyBanc Capital Markets -- Overweight -- $27 Nov. 21, 2025
Upgrade ELAN Argus Hold Buy -- $25 Nov. 19, 2025
Upgrade ELAN JP Morgan Neutral Overweight -- $24 Oct. 7, 2025
Upgrade ELAN Leerink Partners Market Perform Outperform -- $18 July 17, 2025
Upgrade ELAN William Blair Market Perform Outperform -- -- June 26, 2025
Initiation ELAN UBS -- Buy -- $18 Dec. 9, 2024
Downgrade ELAN Morgan Stanley Overweight Equal Weight $17 $15 Sept. 19, 2024

News

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out
ELAN
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
ELAN
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.

Read More
image for news Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
ELAN
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.

Read More
image for news Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

About Elanco Animal Health Incorporated (ELAN)

  • IPO Date 2018-09-20
  • Website https://www.elanco.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Jeffrey N. Simmons
  • Employees 9000

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.